IFNB1 and relapsing-remitting multiple sclerosis: Since the objectives are different, the populations included were also different: in our study, a homogeneous cohort of treatment naïve relapsing-remitting MS patients with at least one relapse in the previous year and achieving criteria to start treatment was selected to evaluate clinical response after beginning IFN-β treatment.